Natera Oncology

ICYMI | Watch this incredible webinar and Q+A session to learn how MRD testing in melanoma care informs patient outcomes. Ask the Expert: MRD Testing for Melanoma -- The Next Steps in Recurrence Prevention Watch here: https://ow.ly/7rOQ50Uw5SZ

Hello from #SABCS24! 👋 Swing by booth #1449 to speak to Team Natera! And don't miss the latest Signatera data in our upcoming presentations throughout the event. Pictured from left to right: David Sudyka, Lindsey Carlblom, Ryan Palusak, Christian Cockerham

It's time for the 2024 San Antonio Breast Cancer Symposium (SABCS)! Say hello to our team at booth # 1449, and don't miss our featured abstract presentations highlighting the latest Signatera data in breast cancer from our experts. “We are proud to share this new data on Signatera at SABCS that underscores our commitment to generating evidence on the clinical utility of Signatera for patients with breast cancer,” said Angel A. Rodriguez, MD, senior medical director for oncology at Natera. #Natera #Signatera #SABCS24 San Antonio Breast Cancer Symposium

Join this upcoming webinar for the opportunity to learn from an expert in melanoma research and gain firsthand insights from a patient advocate. Whether you're a healthcare professional, a patient, or a caregiver, this session will deepen your understanding of MRD testing and its potential to redefine melanoma surveillance. #MRD #Natera #Melanoma https://ow.ly/vpmY50UmNSA Melanoma Research Foundation

Hear from Alexey Aleshin, MD, GM of oncology/ECD, and chief medical officer at Natera as he presents in OncoDaily's inaugural event, Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer. https://ow.ly/HsZC50Ug3Gh #Natera #Oncology

In 2024, an estimated 234,580 Americans will be diagnosed with lung cancer. Natera stands with patients, caregivers, clinicians, researchers, and industry partners all working together to eradicate Lung cancer. #LungCancerAwareness #LCSM #LCAM

New Signatera will be presented data at the San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 10-13 in San Antonio, TX. Natera and its collaborators will present a total of six abstracts. “We are proud to share this new data on Signatera at SABCS that underscores our commitment to generating evidence on the clinical utility of Signatera for patients with breast cancer,” said Angel A. Rodriguez, MD, senior medical director at Natera. Read more about these presentations below. https://ow.ly/c03i50Ug9Ji #Natera #SABCS24 #Signatera

Key milestone surpassed: Over 100 peer-reviewed publications on Signatera, our personalized and tumor-informed molecular residual disease (MRD) test. “Natera has always had a focus on developing robust clinical evidence,” said Alexey Aleshin, MD, chief medical officer and general manager of oncology. “The ongoing delivery of high-quality data is critical to our mission as we work to positively impact cancer care for patients and their families. We want to thank our patients for participating in these studies and our collaborators for their partnership on these efforts.” Multiple validation studies on Signatera have been published in top-tier journals like @Nature, Nature Medicine, Nature Cancer, Journal of Clinical Oncology, Annals of Research in Oncology, and JAMA Oncology. These include some of the largest and most comprehensive prospective studies of MRD testing to date. https://ow.ly/z6t850UcUim #Natera #MRDTesting #Signatera

Over nearly two decades, we've demonstrated that mission-driven entrepreneurship can revolutionize healthcare. By bridging engineering, biology, and genetics, our team has expanded from IVF to transformative diagnostics in prenatal care, oncology, and organ health. Our journey proves that constraints can be catalysts for innovation, and believing in scientific integrity is the ultimate competitive advantage. Hear more from our founders Matthew Rabinowitz and Jonathan Sheena, plus CEO Steve Chapman, and Naterans Chitra Kotwaliwale, Ph.D. and Sarah Elliott (Berridge) in this Crucible Moments podcast episode from Sequoia Capital. https://ow.ly/HASF50UbK1F

November is #LungCancerAwareness Month. Natera's Signatera test measures circulating tumor DNA for lung cancer, monitoring recurrence and tumor growth. This information can help patients and their care teams make better-informed decisions about care. Learn more: https://ow.ly/8BZ550U5sKl